High Risk Neuroblastoma — Trials

High Risk Neuroblastoma — Trials · CancerIndex

Clinical trials

Registered studies

18 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 11
Recruiting: 7
Ph III recruiting: 0
Growth YoY: —
Industry share: 9%
Top sponsor: Memorial Sloan Kettering Cancer Center
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (5)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03786783	Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma	completed	Phase 2	42	National Cancer Institute (NCI)NIH	3	Jun 2, 2026	clinicaltrials

Data updated 22 days agoSource updated Jun 2, 2026source: clinicaltrials